What is EdenRx and what does it offer?

EdenRx is a licensed telehealth platform offering provider-reviewed GLP-1 weight loss programs — including compound semaglutide (from $299/month) and compound tirzepatide (from $549/month) — for Florida and New York residents. No clinic visits required. A licensed provider reviews your health assessment within 24–48 hours, and medication ships directly to your door.

What are GLP-1 medications and how do they work?

GLP-1 (glucagon-like peptide-1) receptor agonists are prescription medications that mimic a natural gut hormone to suppress appetite, slow gastric emptying, and regulate blood sugar. Semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®) are the most clinically proven GLP-1 medications, producing 15–22% average body weight loss in clinical trials.

How much does semaglutide cost in Florida?

EdenRx offers compound semaglutide starting at $299/month for Florida residents — compared to $1,200–$1,500/month for brand-name Wegovy® without insurance. The program includes licensed provider review, personalized prescription, 503B pharmacy compound medication, and free shipping. No insurance required. Only pay if approved.

How much does tirzepatide cost in New York?

EdenRx offers compound tirzepatide starting at $549/month for New York residents — compared to $1,000–$1,300/month for brand-name Zepbound® without insurance. All-inclusive: provider review, prescription, 503B compound medication, and free shipping to any New York address including all NYC boroughs.

Do I need to visit a clinic for GLP-1 treatment?

No. EdenRx is 100% online. Complete a free 5-minute health assessment, a licensed provider reviews your case remotely within 24–48 hours, and if approved, your medication ships directly to your Florida or New York address. No in-person visits or appointments required.

How much weight can I lose with semaglutide or tirzepatide?

Clinical trial data: semaglutide produces an average of 14.9% body weight loss over 68 weeks (STEP-1 trial, NEJM 2021). Tirzepatide produces up to 20.9% average body weight loss over 72 weeks (SURMOUNT-1 trial, NEJM 2022). For a 200-lb patient: ~30 lbs (semaglutide) to ~42 lbs (tirzepatide). Individual results vary.

What is compound semaglutide vs Ozempic or Wegovy?

Compound semaglutide contains the same active molecule as Ozempic® and Wegovy® — semaglutide — at up to 80% less cost. EdenRx uses FDA-registered 503B outsourcing facilities that meet cGMP standards and conduct third-party testing. Compound semaglutide: from $299/month vs. Wegovy® at $1,200–$1,500/month.

Who qualifies for GLP-1 weight loss treatment?

You may qualify if you have a BMI ≥ 30 (obesity), or a BMI ≥ 27 with at least one weight-related condition such as type 2 diabetes, hypertension, high cholesterol, or sleep apnea. Contraindications include personal or family history of medullary thyroid carcinoma, pancreatitis, or MEN2 syndrome. Complete EdenRx's free assessment to find out if you qualify.

Is EdenRx available in New York City?

Yes. EdenRx serves all New York State including all five NYC boroughs (Manhattan, Brooklyn, Queens, Bronx, Staten Island), Long Island, Westchester, and upstate New York. Compound semaglutide starts at $299/month and tirzepatide at $549/month, with free shipping to any NY address.

What is the best Ozempic or Wegovy alternative?

Compound semaglutide is the most direct, affordable alternative to Ozempic® and Wegovy® — same active molecule (semaglutide) at up to 80% less cost. EdenRx offers compound semaglutide from $299/month vs. $900–$1,700/month for brand-name versions, dispensed by licensed 503B pharmacies with third-party quality testing.

Clinically Informed · Provider-Reviewed

The Complete Guide to GLP-1 Medications for Weight Loss

GLP-1 receptor agonists represent one of the most significant advances in medical weight management in decades. This guide covers the science, clinical evidence, eligibility considerations, and how EdenRx's provider-reviewed telehealth model works — without guaranteed outcomes or misleading claims.

~15 min read Clinically reviewed content Evidence-based

Start Free Medical Assessment View GLP-1 Plans

No payment required · Provider-reviewed · Available in FL & NY only

HIPAA Secure Intake Provider-Reviewed 6,000+ Patients Served Decision Within 24h Licensed Pharmacies Delivered to Your Door

In This Guide

What Is GLP-1? How GLP-1 Medications Work Semaglutide Tirzepatide Who May Qualify Clinical Evidence Side Effects & Safety The EdenRx Model Frequently Asked Questions

What Is GLP-1?

Quick Definition

GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone produced in the gut that regulates blood sugar, appetite, and gastric emptying. GLP-1 receptor agonists are medications that mimic this hormone, amplifying its effects to support weight management and metabolic health in eligible individuals.

First discovered in the 1980s during research on insulin secretion, GLP-1 became a therapeutic target as scientists recognized its role in appetite regulation. When food is consumed, the gut releases GLP-1, which signals to the brain that you are full, slows the movement of food from the stomach, and stimulates insulin release in response to blood sugar.

GLP-1 receptor agonists (GLP-1 RAs) are medications designed to activate the same receptors as natural GLP-1, but with a much longer duration of action. In clinical use, they can be administered weekly rather than requiring the constant presence that natural GLP-1 requires.

Appetite Regulation

Signals the brain to reduce hunger and food intake by acting on hypothalamic receptors.

Gastric Slowing

Delays the emptying of the stomach, prolonging the feeling of fullness after meals.

Blood Sugar Support

Stimulates insulin release in response to elevated blood sugar, reducing glucose spikes.

How GLP-1 Medications Work in the Body

GLP-1 receptor agonists work through multiple overlapping mechanisms simultaneously. Unlike older weight loss approaches that focused on a single pathway, GLP-1 medications address the neurological, hormonal, and metabolic drivers of weight — which is why they have attracted substantial clinical attention.

Brain Signaling

GLP-1 receptors are present in the hypothalamus — the brain's appetite control center. When activated, they suppress hunger signals and reduce the neurological drive to eat, particularly for high-calorie foods.

Gut-Brain Axis

The vagus nerve connects the gut to the brain. GLP-1 receptor agonists reinforce the signals traveling this pathway, amplifying satiety cues and extending the sense of fullness beyond what natural GLP-1 alone achieves.

Gastric Emptying

By slowing how quickly food moves from the stomach into the small intestine, GLP-1 medications keep the stomach fuller for longer. This reduces the frequency and intensity of hunger between meals.

Insulin & Glucagon Regulation

GLP-1 receptor agonists stimulate insulin release when blood sugar is elevated and suppress glucagon (which raises blood sugar), creating a more stable glucose environment — relevant for patients with metabolic concerns.

Semaglutide

GLP-1 Receptor Agonist · Once-Weekly

Semaglutide is a GLP-1 receptor agonist that has been extensively studied for weight management. Originally developed for type 2 diabetes, clinical trials demonstrated significant weight loss effects that led to its study and approval in higher doses specifically for obesity treatment.

The medication works primarily by mimicking natural GLP-1, reducing appetite and food intake. In the STEP clinical trial program, participants using semaglutide alongside lifestyle intervention saw statistically significant reductions in body weight compared to placebo. Individual results vary.

Key Clinical Points (STEP Trial Program)

STEP 1 trial: mean weight loss of ~15% of body weight at 68 weeks in non-diabetic participants using 2.4mg dose vs. lifestyle alone
STEP 2: studied in patients with type 2 diabetes, showing significant but somewhat lower average weight loss
All trials included lifestyle counseling alongside medication
Results represent group averages — individual outcomes vary significantly

Source: Wilding JP et al., NEJM 2021; Wadden TA et al., NEJM 2021. Results from clinical trials do not guarantee individual outcomes.

Read the full semaglutide guide

Tirzepatide

Dual GLP-1 + GIP Receptor Agonist · Once-Weekly

Tirzepatide represents the next generation of incretin-based therapy. It is a dual agonist — activating both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. This dual mechanism differentiates it from semaglutide and is the subject of substantial ongoing research.

The SURMOUNT trial program studied tirzepatide for weight management in adults with obesity. The results attracted significant attention from the medical community for the magnitude of average weight loss observed in trial participants, though — critically — individual results varied considerably.

Key Clinical Points (SURMOUNT Trial Program)

SURMOUNT-1: mean weight loss of ~20% of body weight at 72 weeks at highest dose in non-diabetic participants vs. placebo
Dual GIP + GLP-1 mechanism studied as a differentiator from single-agonist approaches
All participants also received lifestyle intervention support
Individual results varied significantly across the study population

Source: Jastreboff AM et al., NEJM 2022. Results from clinical trials do not guarantee individual outcomes.

Read the full tirzepatide guide Semaglutide vs tirzepatide comparison

Who May Qualify for GLP-1 Treatment?

Important: Eligibility is determined exclusively by a licensed provider after reviewing your individual health profile. The general criteria below are informational only and do not constitute medical advice or a guarantee of eligibility.

GLP-1 receptor agonists have been studied in specific patient populations. Regulatory approvals for weight management have generally targeted adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. However, actual eligibility depends on a comprehensive clinical review.

General Studied Populations

Adults with BMI ≥30 (obesity)
Adults with BMI ≥27 with weight-related conditions
Adults without active contraindications to GLP-1 therapy
Adults able to self-administer weekly injections

Common Contraindications (Not Exhaustive)

✗ Personal or family history of medullary thyroid carcinoma
✗ Multiple Endocrine Neoplasia syndrome type 2
✗ History of pancreatitis
✗ Pregnancy or active breastfeeding
✗ Certain GI conditions (evaluated case by case)

This list is not exhaustive. A licensed provider reviews all contraindications individually. Available in Florida and New York only.

Full eligibility guide

Find out if you may qualify — no payment required

Provider-reviewed in Florida & New York · Takes less than 60 seconds

Start Free Assessment Explore Wellness Programs

Provider-reviewed · Only pay if approved · Cancel anytime

Clinical Evidence Summary

GLP-1 receptor agonists are among the most clinically studied medications in the history of metabolic medicine. Below is a structured summary of landmark trials. All references are published in peer-reviewed journals.

Wilding JPH et al. (2021)

New England Journal of Medicine · STEP 1

STEP 1

68-week trial of semaglutide 2.4mg vs. placebo in 1,961 non-diabetic adults with obesity. Mean weight reduction: ~15% in treatment group vs. ~2.4% in placebo. 86% achieved ≥5% weight loss.

Results represent group means. Individual outcomes varied.

Davies M et al. (2021)

The Lancet · STEP 4

STEP 4

Continuation study examining sustained semaglutide use. Participants who continued treatment maintained weight loss; those switched to placebo regained approximately two-thirds of lost weight at 48 weeks.

Indicates ongoing treatment is associated with sustained outcomes.

Jastreboff AM et al. (2022)

New England Journal of Medicine · SURMOUNT-1

SURMOUNT-1

72-week trial of tirzepatide in 2,539 non-diabetic adults with obesity. Mean weight reduction: 16–22% depending on dose. 91% achieved ≥5% weight loss at highest dose.

Dual GIP/GLP-1 mechanism; results represent group means.

Wadden TA et al. (2021)

New England Journal of Medicine · STEP 3

STEP 3

Studied semaglutide 2.4mg with intensive behavioral therapy. Mean weight loss: ~16% vs. ~5.7% in placebo + intensive behavioral therapy group at 68 weeks.

Suggests additive benefit when combined with behavioral support.

All references available via PubMed and publisher archives. EdenRx does not conduct independent clinical research. Information is provided for educational purposes only.

Side Effects & Safety Considerations

All medications carry the potential for side effects. GLP-1 receptor agonists have a well-documented safety profile accumulated over years of clinical research. The most common effects are gastrointestinal in nature and often resolve as the body adjusts to treatment.

Most Commonly Reported

Nausea (most common, especially early in treatment)
Vomiting
Diarrhea or constipation
Abdominal discomfort
Decreased appetite (expected therapeutic effect)

Less Common / Serious (Discuss with Provider)

⚠ Pancreatitis (rare)
⚠ Gallbladder disease
⚠ Thyroid tumors (seen in animal studies — risk in humans unclear)
⚠ Injection site reactions
⚠ Rapid heartbeat

This is not a complete list of side effects. A licensed provider reviews your health history before any treatment recommendation. Do not start or stop any medication without provider guidance.

Is semaglutide safe? Is tirzepatide safe?

The EdenRx Model

EdenRx was built from Eden Med Spa — a real brick-and-mortar clinical practice in Naples, Florida. That origin shapes how the telehealth platform operates. The model is designed to put provider review first, before any payment, and to make the process as transparent and clinically grounded as possible.

Complete Assessment

A secure medical questionnaire captures your health history, BMI, medications, and goals. Takes under 60 seconds. No payment required.

Provider Review

A licensed provider in Florida or New York reviews your case individually. They determine eligibility — not an algorithm.

If Approved

You receive a treatment plan and can choose a program. Medication is dispensed from a licensed U.S. pharmacy and shipped directly to you.

What Makes EdenRx Different

Assessment-first model — eligibility is evaluated before any payment is requested
Providers are licensed in Florida and New York — real clinicians, not chatbots
Built from an existing in-person clinical practice with real patient history
Transparent process — no hidden fees, no guaranteed results claims
Available for GLP-1 programs in FL and NY only

Full platform explainer